Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREeMPT: MRD-Guided Maintenance Therapy Post-HCT for Myeloid Malignancies
NCT07572929Phase 2Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2026
- Primary completion
- Feb 2034
- Countries
- 1
01
Overview
Phase 2, open-label trial in Myeloid malignancy, myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN) and 1 more (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Relapse-Free Survival at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
Myeloid malignancymyelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07572929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572929.